daptomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 783 103060-53-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • daptomycin
  • cidecin
  • cubicin
  • dapcin
  • daptomicina
  • daptomycine
  • daptomycinum
  • LY146032
  • LY-146032
  • deptomycin
A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA.
  • Molecular weight: 1620.69
  • Formula: C72H101N17O26
  • CLOGP: -1.85
  • LIPINSKI: 3
  • HAC: 43
  • HDO: 22
  • TPSA: 702.02
  • ALOGS: -4.97
  • ROTB: 35

Drug dosage:

DoseUnitRoute
0.28 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1000 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 40.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.47 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.09 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.08 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.10 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Sept. 12, 2003 FDA CUBIST
July 1, 2011 PMDA MSD K.K

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eosinophilic pneumonia 532.13 26.60 109 9910 2664 90615764
Blood creatine phosphokinase increased 483.03 26.60 170 9849 33853 90584575
Rhabdomyolysis 439.30 26.60 177 9842 51079 90567349
Eosinophilia 437.40 26.60 151 9868 28382 90590046
Eosinophilic pneumonia acute 318.35 26.60 57 9962 658 90617770
Drug reaction with eosinophilia and systemic symptoms 289.83 26.60 125 9894 42633 90575795
Product use in unapproved indication 287.39 26.60 261 9758 335975 90282453
Pathogen resistance 275.97 26.60 79 9940 8036 90610392
Hepatic cytolysis 258.56 26.60 105 9914 30811 90587617
Acute kidney injury 256.74 26.60 240 9779 320147 90298281
Agranulocytosis 178.72 26.60 84 9935 34918 90583510
Neutropenia 145.24 26.60 150 9869 224754 90393674
Encephalopathy 134.19 26.60 76 9943 46368 90572060
Rash maculo-papular 131.98 26.60 72 9947 40861 90577567
Cholestasis 120.22 26.60 65 9954 36234 90582194
Diffuse large B-cell lymphoma refractory 105.81 26.60 27 9992 1773 90616655
Pneumonitis 103.17 26.60 63 9956 44107 90574321
Staphylococcal bacteraemia 100.79 26.60 36 9983 7433 90610995
Protothecosis 93.16 26.60 19 10000 452 90617976
Bacteraemia 91.17 26.60 46 9973 22254 90596174
Drug resistance 88.39 26.60 50 9969 30399 90588029
Off label use 86.51 26.60 292 9727 1101960 89516468
Chills 84.99 26.60 88 9931 131893 90486535
Toxic skin eruption 77.84 26.60 37 9982 15737 90602691
Candida infection 72.99 26.60 46 9973 34011 90584417
Leukopenia 70.00 26.60 70 9949 100640 90517788
Drug interaction 69.65 26.60 116 9903 276337 90342091
Arthritis bacterial 68.10 26.60 27 9992 7418 90611010
Interstitial lung disease 66.21 26.60 60 9959 76345 90542083
Multiple organ dysfunction syndrome 65.87 26.60 57 9962 68279 90550149
Brain abscess 63.61 26.60 20 9999 2792 90615636
Toxic epidermal necrolysis 62.45 26.60 41 9978 32487 90585941
Tubulointerstitial nephritis 61.35 26.60 37 9982 25306 90593122
Pancytopenia 59.73 26.60 70 9949 120193 90498235
Sepsis 58.60 26.60 85 9934 179729 90438699
Fusarium infection 57.60 26.60 15 10004 1067 90617361
Pyrexia 56.92 26.60 181 9838 660304 89958124
Pulmonary toxicity 56.74 26.60 27 9992 11504 90606924
Systemic candida 56.13 26.60 21 9998 4938 90613490
Intracranial infection 55.85 26.60 11 10008 218 90618210
Drug ineffective 55.38 26.60 299 9720 1383999 89234429
Symmetrical drug-related intertriginous and flexural exanthema 54.19 26.60 14 10005 965 90617463
Enterococcal infection 54.12 26.60 25 9994 9966 90608462
Thrombocytopenia 51.74 26.60 87 9932 208638 90409790
Mixed liver injury 50.63 26.60 22 9997 7601 90610827
Lactic acidosis 50.47 26.60 43 9976 50420 90568008
Acute generalised exanthematous pustulosis 46.63 26.60 25 9994 13678 90604750
Stevens-Johnson syndrome 44.50 26.60 32 9987 29344 90589084
Glomerular filtration rate abnormal 40.85 26.60 12 10007 1333 90617095
Headache 39.93 26.60 23 9996 862723 89755705
Staphylococcal infection 39.92 26.60 37 9982 48402 90570026
Rash 39.43 26.60 183 9836 795917 89822511
Eosinophil count increased 39.36 26.60 22 9997 13059 90605369
Osteomyelitis 39.16 26.60 29 9990 27817 90590611
Acute respiratory failure 37.75 26.60 34 9985 42884 90575544
Band neutrophil count decreased 36.44 26.60 7 10012 121 90618307
Drug intolerance 35.52 26.60 4 10015 447587 90170841
Asymptomatic bacteriuria 35.36 26.60 8 10011 314 90618114
Septic pulmonary embolism 35.11 26.60 7 10012 148 90618280
Imprisonment 34.88 26.60 8 10011 334 90618094
Hyperkalaemia 34.22 26.60 39 9980 64925 90553503
Abdominal discomfort 33.83 26.60 6 10013 477322 90141106
Hyperoxaluria 33.65 26.60 7 10012 184 90618244
Alopecia 33.45 26.60 7 10012 495064 90123364
Lung opacity 32.21 26.60 15 10004 6087 90612341
Enterococcal bacteraemia 32.05 26.60 11 10008 2017 90616411
Bacterial infection 32.03 26.60 24 9995 23420 90595008
Pain 31.97 26.60 38 9981 996303 89622125
Brain oedema 31.16 26.60 21 9998 17364 90601064
Linear IgA disease 30.82 26.60 11 10008 2263 90616165
Enterococcal sepsis 30.43 26.60 10 10009 1606 90616822
Dermatitis exfoliative generalised 30.31 26.60 14 10005 5579 90612849
Gastrointestinal candidiasis 30.12 26.60 7 10012 310 90618118
Cutaneous vasculitis 29.86 26.60 15 10004 7178 90611250
Acute respiratory distress syndrome 29.81 26.60 25 9994 28661 90589767
Disseminated intravascular coagulation 29.32 26.60 22 9997 21516 90596912
Nasopharyngitis 29.10 26.60 5 10014 407099 90211329
Cholestatic liver injury 28.66 26.60 12 10007 3785 90614643
Neoplasm progression 27.41 26.60 29 9990 44457 90573971
Fungal sepsis 26.88 26.60 9 10010 1532 90616896
Intervertebral discitis 26.65 26.60 12 10007 4508 90613920

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eosinophilic pneumonia 1849.17 22.18 417 15773 4457 42600688
Eosinophilic pneumonia acute 790.51 22.18 152 16038 665 42604480
Eosinophilia 519.27 22.18 252 15938 32647 42572498
Drug reaction with eosinophilia and systemic symptoms 433.19 22.18 242 15948 41833 42563312
Product use in unapproved indication 365.00 22.18 397 15793 184059 42421086
Blood creatine phosphokinase increased 326.15 22.18 212 15978 48126 42557019
Interstitial lung disease 279.30 22.18 234 15956 78228 42526917
Pneumonitis 278.97 22.18 182 16008 41536 42563609
Rhabdomyolysis 245.75 22.18 217 15973 77802 42527343
Acute kidney injury 220.67 22.18 451 15739 366886 42238259
Antimicrobial susceptibility test resistant 217.47 22.18 46 16144 350 42604795
Pathogen resistance 205.66 22.18 96 16094 11354 42593791
Agranulocytosis 193.48 22.18 129 16061 30483 42574662
Cholestasis 192.18 22.18 132 16058 32747 42572398
Hypersensitivity pneumonitis 189.86 22.18 57 16133 1947 42603198
Drug dispensed to wrong patient 136.33 22.18 33 16157 484 42604661
Hepatic cytolysis 118.58 22.18 91 16099 26753 42578392
Drug resistance 113.12 22.18 98 16092 34150 42570995
Minimum inhibitory concentration 111.68 22.18 23 16167 151 42604994
Cardiac valve vegetation 109.84 22.18 28 16162 513 42604632
Therapeutic response delayed 106.59 22.18 29 16161 690 42604455
Chills 104.22 22.18 152 16038 93914 42511231
Thrombocytopenia 98.96 22.18 221 15969 190058 42415087
Off label use 98.41 22.18 489 15701 637846 41967299
Toxic epidermal necrolysis 81.23 22.18 73 16117 26677 42578468
Rash maculo-papular 81.23 22.18 85 16105 37418 42567727
Fatigue 78.21 22.18 34 16156 435607 42169538
Alveolar lung disease 74.91 22.18 20 16170 442 42604703
Kounis syndrome 72.33 22.18 32 16158 3336 42601809
Lung disorder 72.20 22.18 90 16100 47833 42557312
Treatment failure 71.93 22.18 103 16087 62521 42542624
Drug ineffective for unapproved indication 71.64 22.18 88 16102 46075 42559070
Staphylococcal bacteraemia 70.52 22.18 47 16143 11074 42594071
Wrong patient received product 70.43 22.18 32 16158 3551 42601594
Diffuse alveolar damage 70.11 22.18 29 16161 2563 42602582
Pulmonary interstitial emphysema syndrome 66.48 22.18 19 16171 544 42604601
Enterococcal infection 64.82 22.18 46 16144 11993 42593152
Multiple organ dysfunction syndrome 63.53 22.18 124 16066 96911 42508234
Hepatitis cholestatic 63.45 22.18 42 16148 9782 42595363
Pyrexia 60.39 22.18 302 15888 393740 42211405
Expired product administered 59.89 22.18 30 16160 4133 42601012
Staphylococcal infection 58.79 22.18 72 16118 37571 42567574
Hepatocellular injury 55.47 22.18 56 16134 23622 42581523
Fall 55.27 22.18 11 16179 234509 42370636
Diarrhoea 54.53 22.18 57 16133 460792 42144353
Drug ineffective 53.13 22.18 414 15776 629783 41975362
Vascular pseudoaneurysm thrombosis 52.92 22.18 11 16179 76 42605069
Candida infection 52.26 22.18 52 16138 21558 42583587
Osteomyelitis fungal 51.22 22.18 14 16176 339 42604806
Bacteraemia 49.34 22.18 54 16136 24986 42580159
Wrong product administered 48.60 22.18 30 16160 6196 42598949
Product dispensing error 45.36 22.18 31 16159 7608 42597537
Arteriospasm coronary 45.25 22.18 26 16164 4712 42600433
Systemic candida 45.04 22.18 27 16163 5292 42599853
Septic shock 44.76 22.18 104 16086 91568 42513577
Pulmonary eosinophilia 44.74 22.18 12 16178 270 42604875
Acute interstitial pneumonitis 44.16 22.18 14 16176 574 42604571
Product storage error 43.21 22.18 35 16155 11105 42594040
Aortoenteric fistula 42.93 22.18 10 16180 123 42605022
Dizziness 42.22 22.18 21 16169 249233 42355912
Myositis 42.05 22.18 39 16151 14827 42590318
Product dose omission issue 41.42 22.18 5 16185 154360 42450785
Weight decreased 40.90 22.18 14 16176 207934 42397211
Respiratory failure 38.95 22.18 122 16068 128010 42477135
Renal tubular necrosis 38.65 22.18 41 16149 18313 42586832
Acute generalised exanthematous pustulosis 37.62 22.18 29 16161 8566 42596579
Organising pneumonia 36.48 22.18 27 16163 7505 42597640
Stevens-Johnson syndrome 35.55 22.18 43 16147 22135 42583010
Lower respiratory tract infection 35.00 22.18 59 16131 41147 42563998
Acute respiratory distress syndrome 33.78 22.18 49 16141 30059 42575086
Hypertension 33.31 22.18 11 16179 167193 42437952
Aspergillus infection 32.68 22.18 35 16155 15802 42589343
Leukopenia 32.39 22.18 81 16109 74665 42530480
Eosinophil count increased 31.92 22.18 29 16161 10734 42594411
Haemodynamic instability 31.81 22.18 31 16159 12526 42592619
Pain 31.53 22.18 28 16162 244820 42360325
Oliguria 31.43 22.18 27 16163 9286 42595859
Hyperammonaemia 31.11 22.18 25 16165 7841 42597304
Pulmonary toxicity 31.07 22.18 26 16164 8629 42596516
Encephalopathy 30.96 22.18 56 16134 41277 42563868
Product administration error 30.11 22.18 36 16154 18307 42586838
Vomiting 29.72 22.18 40 16150 289683 42315462
Nausea 29.62 22.18 67 16123 396732 42208413
Toxic skin eruption 29.49 22.18 31 16159 13699 42591446
Anxiety 29.10 22.18 5 16185 118555 42486590
Depression 28.91 22.18 4 16186 111359 42493786
Rectal perforation 28.86 22.18 10 16180 542 42604603
Constipation 28.49 22.18 13 16177 162278 42442867
Tremor 28.25 22.18 91 16099 96838 42508307
Arthralgia 28.22 22.18 22 16168 205216 42399929
Pain in extremity 28.14 22.18 11 16179 150593 42454552
Hypokinesia 28.11 22.18 26 16164 9845 42595300
Death 28.06 22.18 89 16101 471096 42134049
Headache 27.78 22.18 30 16160 239339 42365806
Embolic cerebral infarction 27.66 22.18 11 16179 878 42604267
Lung infiltration 27.26 22.18 30 16160 13959 42591186
Insomnia 26.89 22.18 6 16184 118247 42486898
Spinal cord disorder 26.84 22.18 11 16179 949 42604196
Nephritis allergic 26.60 22.18 10 16180 686 42604459
Asthenia 26.60 22.18 41 16149 280752 42324393
Abdominal pain 25.46 22.18 21 16169 190450 42414695
Drug eruption 25.08 22.18 37 16153 23038 42582107
Enterobacter pneumonia 24.90 22.18 9 16181 552 42604593
Myasthenia gravis crisis 24.70 22.18 10 16180 836 42604309
Intervertebral discitis 24.40 22.18 15 16175 3075 42602070
Gait disturbance 24.34 22.18 4 16186 97996 42507149
Endocarditis 24.24 22.18 22 16168 8130 42597015
Toxicity to various agents 24.13 22.18 31 16159 229105 42376040
Haemophagocytic lymphohistiocytosis 23.94 22.18 32 16158 18190 42586955
Uraemic encephalopathy 23.41 22.18 8 16182 416 42604729
Generalised oedema 23.39 22.18 29 16161 15307 42589838
Neutropenia 23.11 22.18 142 16048 199289 42405856
Chimerism 22.98 22.18 7 16183 251 42604894
Wound drainage 22.79 22.18 9 16181 705 42604440
Brief psychotic disorder with marked stressors 22.57 22.18 7 16183 267 42604878
Therapy non-responder 22.25 22.18 57 16133 53302 42551843

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eosinophilic pneumonia 2728.37 20.77 562 24439 6665 110557633
Eosinophilic pneumonia acute 1113.01 20.77 209 24792 1456 110562842
Eosinophilia 1052.92 20.77 420 24581 57516 110506782
Blood creatine phosphokinase increased 743.56 20.77 352 24649 72725 110491573
Drug reaction with eosinophilia and systemic symptoms 734.32 20.77 362 24639 81733 110482565
Rhabdomyolysis 633.01 20.77 373 24628 120028 110444270
Product use in unapproved indication 592.52 20.77 610 24391 446767 110117531
Acute kidney injury 507.87 20.77 668 24333 634762 109929536
Pathogen resistance 423.84 20.77 157 24844 17515 110546783
Interstitial lung disease 391.09 20.77 292 24709 139042 110425256
Agranulocytosis 379.44 20.77 212 24789 61548 110502750
Pneumonitis 375.52 20.77 227 24774 76304 110487994
Hepatic cytolysis 338.22 20.77 189 24812 54864 110509434
Cholestasis 331.08 20.77 197 24804 64321 110499977
Pulmonary eosinophilia 297.13 20.77 61 24940 703 110563595
Hypersensitivity pneumonitis 253.74 20.77 79 24922 5186 110559112
Antimicrobial susceptibility test resistant 230.91 20.77 45 24956 389 110563909
Rash maculo-papular 209.00 20.77 156 24845 74066 110490232
Drug resistance 184.94 20.77 130 24871 56244 110508054
Staphylococcal bacteraemia 174.37 20.77 82 24919 16606 110547692
Thrombocytopenia 172.63 20.77 294 24707 348591 110215707
Chills 167.87 20.77 211 24790 190369 110373929
Off label use 146.11 20.77 696 24305 1499489 109064809
Encephalopathy 143.29 20.77 130 24871 80925 110483373
Multiple organ dysfunction syndrome 141.64 20.77 173 24828 151537 110412761
Toxic epidermal necrolysis 141.58 20.77 111 24890 56616 110507682
Drug dispensed to wrong patient 135.92 20.77 32 24969 717 110563581
Neutropenia 131.94 20.77 273 24728 374347 110189951
Drug ineffective 131.33 20.77 682 24319 1519858 109044440
Cardiac valve vegetation 125.49 20.77 32 24969 1008 110563290
Minimum inhibitory concentration 123.72 20.77 23 24978 150 110564148
Bacteraemia 116.83 20.77 88 24913 42302 110521996
Pyrexia 105.21 20.77 441 24560 897824 109666474
Candida infection 105.05 20.77 87 24914 47922 110516376
Systemic candida 101.09 20.77 48 24953 9926 110554372
Therapeutic response delayed 98.04 20.77 28 24973 1362 110562936
Enterococcal infection 96.15 20.77 59 24942 20307 110543991
Leukopenia 94.94 20.77 141 24860 148650 110415648
Fatigue 94.45 20.77 82 24919 1215876 109348422
Toxic skin eruption 86.84 20.77 62 24939 27453 110536845
Headache 83.57 20.77 48 24953 882329 109681969
Drug ineffective for unapproved indication 82.81 20.77 109 24892 102729 110461569
Pulmonary toxicity 82.73 20.77 51 24950 17695 110546603
Pain 82.16 20.77 58 24943 954897 109609401
Protothecosis 81.49 20.77 20 24981 537 110563761
Hepatocellular injury 81.29 20.77 77 24924 50565 110513733
Stevens-Johnson syndrome 78.52 20.77 73 24928 46828 110517470
Alveolar lung disease 76.42 20.77 20 24981 699 110563599
Pulmonary interstitial emphysema syndrome 75.85 20.77 19 24982 556 110563742
Respiratory failure 75.76 20.77 157 24844 215175 110349123
Diffuse alveolar damage 75.64 20.77 30 24971 4017 110560281
Sepsis 75.17 20.77 202 24799 327144 110237154
Acute respiratory distress syndrome 74.38 20.77 75 24926 53123 110511175
Acute generalised exanthematous pustulosis 73.44 20.77 51 24950 21613 110542685
Tubulointerstitial nephritis 73.11 20.77 75 24926 54209 110510089
Eosinophil count increased 72.38 20.77 50 24951 21008 110543290
Joint swelling 72.07 20.77 8 24993 442837 110121461
Kounis syndrome 70.91 20.77 32 24969 5893 110558405
Pancytopenia 68.14 20.77 148 24853 209465 110354833
Brain abscess 66.82 20.77 32 24969 6742 110557556
Dizziness 66.02 20.77 38 24963 698155 109866143
Fall 65.93 20.77 27 24974 603455 109960843
Hepatitis cholestatic 65.83 20.77 44 24957 17522 110546776
Staphylococcal infection 65.59 20.77 80 24921 69864 110494434
Septic shock 65.22 20.77 123 24878 157405 110406893
Wrong patient received product 64.23 20.77 31 24970 6643 110557655
Aspergillus infection 63.62 20.77 50 24951 25566 110538732
Diarrhoea 62.54 20.77 101 24900 1139404 109424894
Osteomyelitis fungal 60.86 20.77 15 24986 410 110563888
Acute interstitial pneumonitis 58.52 20.77 19 24982 1427 110562871
Alopecia 58.31 20.77 7 24994 364746 110199552
Vascular pseudoaneurysm thrombosis 58.12 20.77 11 24990 80 110564218
Arthritis bacterial 57.95 20.77 34 24967 10786 110553512
Expired product administered 57.77 20.77 31 24970 8289 110556009
Drug intolerance 57.68 20.77 11 24990 406501 110157797
Arthralgia 57.50 20.77 55 24946 779577 109784721
Abdominal discomfort 55.16 20.77 11 24990 393847 110170451
Insomnia 55.06 20.77 8 24993 360582 110203716
Lung disorder 54.98 20.77 124 24877 179923 110384375
Pain in extremity 54.48 20.77 21 24980 487097 110077201
Weight decreased 54.34 20.77 19 24982 468038 110096260
Endocarditis 53.76 20.77 35 24966 13336 110550962
Nasopharyngitis 53.21 20.77 12 24989 394349 110169949
Peripheral swelling 53.12 20.77 13 24988 404021 110160277
Wrong product administered 52.36 20.77 32 24969 10928 110553370
Osteomyelitis 51.89 20.77 52 24949 36548 110527750
Acute respiratory failure 51.86 20.77 74 24927 75186 110489112
Musculoskeletal stiffness 51.19 20.77 3 24998 279819 110284479
Depression 50.94 20.77 6 24995 317329 110246969
Renal tubular necrosis 50.17 20.77 47 24954 30428 110533870
Weight increased 48.76 20.77 17 24984 419627 110144671
Drug eruption 48.09 20.77 60 24941 53599 110510699
Hypertension 47.84 20.77 28 24973 510056 110054242
Anxiety 47.56 20.77 10 24991 345068 110219230
Sinusitis 46.66 20.77 6 24995 296682 110267616
Fusarium infection 46.46 20.77 19 24982 2752 110561546
Abdominal pain upper 46.34 20.77 11 24990 349100 110215198
Aortoenteric fistula 46.32 20.77 10 24991 149 110564149
Tremor 45.57 20.77 124 24877 202108 110362190
Vomiting 45.09 20.77 86 24915 910589 109653709
Swelling 44.78 20.77 12 24989 351029 110213269
Mixed liver injury 44.65 20.77 30 24971 12049 110552249
Therapeutic product effect decreased 43.55 20.77 3 24998 244313 110319985
Intracranial infection 43.43 20.77 11 24990 337 110563961
Cutaneous vasculitis 43.22 20.77 30 24971 12699 110551599
Product dose omission issue 42.98 20.77 10 24991 321772 110242526
Intervertebral discitis 42.88 20.77 24 24977 6966 110557332
Organising pneumonia 42.44 20.77 31 24970 14212 110550086
Dermatitis exfoliative generalised 42.36 20.77 28 24973 10944 110553354
Contraindicated product administered 41.62 20.77 4 24997 248263 110316035
Hypoaesthesia 41.51 20.77 10 24991 314213 110250085
Product dispensing error 40.79 20.77 32 24969 16313 110547985
Rash 40.28 20.77 320 24681 820644 109743654
Myositis 40.11 20.77 42 24959 31074 110533224
Renal failure 39.66 20.77 127 24874 226447 110337851
Arteriospasm coronary 39.51 20.77 25 24976 9075 110555223
Haemodynamic instability 39.03 20.77 36 24965 22852 110541446
Contusion 38.49 20.77 4 24997 233357 110330941
Asthma 37.17 20.77 6 24995 250285 110314013
Enterococcal sepsis 36.84 20.77 17 24984 3295 110561003
Pericarditis 35.51 20.77 4 24997 219110 110345188
Symmetrical drug-related intertriginous and flexural exanthema 35.23 20.77 14 24987 1883 110562415
Disseminated intravascular coagulation 35.15 20.77 45 24956 41241 110523057
Nausea 34.56 20.77 153 24848 1235537 109328761
Maternal exposure during pregnancy 33.88 20.77 8 24993 254875 110309423
Device related infection 33.52 20.77 43 24958 39476 110524822
Lung infiltration 33.10 20.77 34 24967 24594 110539704
Product storage error 32.90 20.77 32 24969 21696 110542602
Product administration error 32.37 20.77 41 24960 37176 110527122
Crystalluria 32.33 20.77 12 24989 1343 110562955
Discomfort 32.21 20.77 5 24996 214702 110349596
Renal impairment 31.50 20.77 104 24897 188341 110375957
Band neutrophil count decreased 31.45 20.77 7 24994 121 110564177
Memory impairment 30.92 20.77 4 24997 196940 110367358
Constipation 30.31 20.77 22 24979 357764 110206534
Hyperammonaemia 30.27 20.77 25 24976 13707 110550591
Asthenia 29.92 20.77 70 24931 688929 109875369
Wound 29.91 20.77 8 24993 234429 110329869
Gastrooesophageal reflux disease 29.89 20.77 3 24998 179973 110384325
Purpura 29.80 20.77 32 24969 24356 110539942
Stomatitis 29.61 20.77 12 24989 270230 110294068
Linear IgA disease 29.48 20.77 16 24985 4373 110559925
Injection site pain 29.46 20.77 3 24998 177919 110386379
Oliguria 29.23 20.77 28 24973 18629 110545669
Hypoprothrombinaemia 28.53 20.77 10 24991 949 110563349
Chorioretinitis 28.24 20.77 11 24990 1404 110562894
Musculoskeletal pain 28.06 20.77 4 24997 183019 110381279
Blood culture positive 27.80 20.77 20 24981 8956 110555342
Rectal perforation 27.77 20.77 10 24991 1027 110563271
Embolic cerebral infarction 27.57 20.77 11 24990 1495 110562803
Nephritis allergic 27.38 20.77 10 24991 1069 110563229
Generalised oedema 26.98 20.77 34 24967 30670 110533628
Enterococcal bacteraemia 26.51 20.77 15 24986 4446 110559852
Gait disturbance 26.44 20.77 15 24986 278193 110286105
Muscle spasms 26.43 20.77 15 24986 278142 110286156
Decreased appetite 26.16 20.77 42 24959 475804 110088494
Septic embolus 26.06 20.77 12 24989 2314 110561984
Glomerular filtration rate abnormal 25.78 20.77 12 24989 2371 110561927
Abdominal pain 25.72 20.77 48 24953 512941 110051357
Palpitations 25.56 20.77 3 24998 159209 110405089
Treatment failure 25.45 20.77 127 24874 277107 110287191
Dyspepsia 25.36 20.77 6 24995 190959 110373339
Disseminated aspergillosis 25.33 20.77 12 24989 2468 110561830
Chimerism 25.06 20.77 7 24994 314 110563984
Drug interaction 25.02 20.77 196 24805 499987 110064311
Arthritis 24.92 20.77 4 24997 167582 110396716
Multiple-drug resistance 24.89 20.77 22 24979 13213 110551085
Mediastinitis 24.79 20.77 10 24991 1398 110562900
Injury 24.69 20.77 5 24996 177260 110387038
Haemophagocytic lymphohistiocytosis 24.69 20.77 33 24968 31526 110532772
Enterobacter pneumonia 24.69 20.77 8 24993 597 110563701
Septic pulmonary embolism 24.68 20.77 7 24994 332 110563966
Soft tissue infection 24.62 20.77 15 24986 5092 110559206
Brief psychotic disorder with marked stressors 24.26 20.77 7 24994 353 110563945
Myalgia 24.16 20.77 107 24894 222274 110342024
Lactic acidosis 24.05 20.77 60 24941 92751 110471547
Osteoarthritis 23.74 20.77 6 24995 182617 110381681
Spinal cord disorder 23.57 20.77 11 24990 2187 110562111
Meningitis enterococcal 23.26 20.77 6 24995 198 110564100
Gouty arthritis 23.21 20.77 10 24991 1649 110562649
Hepatotoxicity 23.17 20.77 47 24954 63353 110500945
Haemolytic anaemia 23.05 20.77 26 24975 20894 110543404
General physical health deterioration 22.94 20.77 38 24963 425257 110139041
Imprisonment 22.91 20.77 8 24993 751 110563547
Myocarditis 22.86 20.77 31 24970 30024 110534274
Ill-defined disorder 22.75 20.77 4 24997 156849 110407449
Splenic embolism 22.65 20.77 6 24995 220 110564078
Endocarditis bacterial 22.40 20.77 10 24991 1795 110562503
Uraemic encephalopathy 22.38 20.77 8 24993 804 110563494
Myasthenia gravis crisis 22.35 20.77 10 24991 1804 110562494
Hypokinesia 22.15 20.77 26 24975 21800 110542498
Wound drainage 22.07 20.77 9 24992 1295 110563003
Gastrointestinal disorder 21.65 20.77 14 24987 241938 110322360
Infusion related reaction 21.55 20.77 33 24968 381129 110183169
Hypertransaminasaemia 21.53 20.77 27 24974 24228 110540070
Sleep disorder 21.47 20.77 9 24992 198635 110365663
Gastrointestinal candidiasis 21.47 20.77 7 24994 533 110563765
Autoimmune anaemia 21.40 20.77 4 24997 27 110564271
Lung opacity 21.18 20.77 19 24982 11633 110552665
Skin test positive 21.15 20.77 9 24992 1440 110562858
Impaired healing 21.12 20.77 9 24992 196708 110367590
Chest pain 20.89 20.77 33 24968 376342 110187956
Type 2 diabetes mellitus 20.88 20.77 7 24994 177225 110387073
Urticarial vasculitis 20.87 20.77 8 24993 978 110563320

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01XX09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Other antibacterials
FDA CS M0519359 Lipopeptides
FDA EPC N0000175509 Lipopeptide Antibacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:76969 bacterial metabolite
CHEBI has role CHEBI:140190 calcium-dependent antibiotics

Related Drugs by ATC class:

J01XX Other antibacterials 12 drugs
bacitracinclofoctolfosfomycingepotidacinlefamulinlinezolidmandelic acidmethenaminenitroxolinespectinomycintedizolid phosphatexibornol

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Secondary infection of erosion and ulcer caused by MRSA indication 266096002
Secondary infection of surgical wounds caused by MRSA indication 308155002
Right-sided Staphylococcus aureus endocarditis indication 426087004
Bacteremia caused by Staphylococcus aureus indication 428763004
Sepsis due to Staphylococcus aureus indication 448417001
Sepsis caused by methicillin resistant Staphylococcus aureus indication 448812000
Secondary infection of trauma, and burn wounds caused by MRSA indication 1176997000
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
Complicated Skin and Skin Structure Enterococcus Faecalis Infection indication
Complicated Skin and Skin Structure Streptococcus Agalactiae Infection indication
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection indication
Complicated Skin and Skin Structure Streptococcus dysgalactiae Infection indication
Diabetic Foot Infection Due to Gram-Positive Bacteria off-label use
Acute nephropathy contraindication 58574008
Diarrhea contraindication 62315008
Disorder of muscle contraindication 129565002 DOID:423
Eosinophilic asthma contraindication 367542003 DOID:9498
Neuropathy contraindication 386033004 DOID:870
Pseudomembranous enterocolitis contraindication 397683000
Increased Creatine Phosphokinase contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.22 acidic
pKa2 3.62 acidic
pKa3 3.96 acidic
pKa4 4.53 acidic
pKa5 12.39 acidic
pKa6 12.68 acidic
pKa7 12.92 acidic
pKa8 13.25 acidic
pKa9 13.31 acidic
pKa10 13.53 acidic
pKa11 13.68 acidic
pKa12 13.81 acidic
pKa13 13.92 acidic
pKa14 10.43 Basic
pKa15 2.61 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** CUBICIN CUBIST PHARMS LLC N021572 Sept. 12, 2003 DISCN POWDER INTRAVENOUS 8003673 Sept. 4, 2028 TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
350MG/VIAL DAPTOMYCIN HOSPIRA N210282 June 21, 2021 RX POWDER INTRAVENOUS 10357535 Sept. 11, 2033 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND S. AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY RECONSTITUTING AND ADMINISTERING THE FORMULATION AS RECITED IN CLAIM 12
350MG/VIAL DAPTOMYCIN HOSPIRA N210282 June 21, 2021 RX POWDER INTRAVENOUS 9655946 Sept. 11, 2033 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY ADMINISTERING THE FORMULATION OF DAPTOMYCIN AS RECITED IN CLAIM 18
500MG/VIAL DAPTOMYCIN HOSPIRA N210282 June 21, 2021 RX POWDER INTRAVENOUS 10357535 Sept. 11, 2033 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND S. AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY RECONSTITUTING AND ADMINISTERING THE FORMULATION AS RECITED IN CLAIM 12
500MG/VIAL DAPTOMYCIN HOSPIRA N210282 June 21, 2021 RX POWDER INTRAVENOUS 9655946 Sept. 11, 2033 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY ADMINISTERING THE FORMULATION OF DAPTOMYCIN AS RECITED IN CLAIM 18
350MG/VIAL DAPTOMYCIN HIKMA N217415 Jan. 30, 2023 RX POWDER INTRAVENOUS 12053502 Aug. 28, 2038 TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOOD STREAM INFECTIONS
500MG/VIAL DAPTOMYCIN HIKMA N217415 Jan. 30, 2023 RX POWDER INTRAVENOUS 12053502 Aug. 28, 2038 TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOOD STREAM INFECTIONS
500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** DAPZURA RT BAXTER HLTHCARE CORP N213645 Jan. 25, 2022 DISCN POWDER INTRAVENOUS 11173189 March 11, 2041 METHOD OF TREATING A BACTERIAL INFECTION BY ADMINISTERING A RECONSTITUTED SOLID FORMULATION OF DAPTOMYCIN CONTAINING 31.0 TO 59.4% WT TOTAL MANNITOL AND SORBITOL

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Outer membrane porin protein OmpD Transporter WOMBAT-PK

External reference:

IDSource
4021414 VUID
N0000148828 NUI
D01080 KEGG_DRUG
22299 RXNORM
C0057144 UMLSCUI
CHEBI:600103 CHEBI
CHEMBL387675 ChEMBL_ID
D017576 MESH_DESCRIPTOR_UI
DB00080 DRUGBANK_ID
10904 IUPHAR_LIGAND_ID
6127 INN_ID
NWQ5N31VKK UNII
21585658 PUBCHEM_CID
17565 MMSL
244166 MMSL
47428 MMSL
d04894 MMSL
003222 NDDF
406438001 SNOMEDCT_US
406439009 SNOMEDCT_US
4021414 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9378 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 28 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9444 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 31 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9445 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 32 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9455 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 34 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9456 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 32 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9465 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 32 sections
Daptomycin in Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-0712 INJECTION, SOLUTION 350 mg INTRAVENOUS NDA 27 sections
Daptomycin in Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-0714 INJECTION, SOLUTION 500 mg INTRAVENOUS NDA 27 sections
Daptomycin in Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-0716 INJECTION, SOLUTION 700 mg INTRAVENOUS NDA 27 sections
Daptomycin in Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-0718 INJECTION, SOLUTION 1000 mg INTRAVENOUS NDA 27 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0120 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 30 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0122 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 30 sections
daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 14335-120 INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 500 mg INTRAVENOUS ANDA 30 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-434 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS ANDA 30 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-434 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS ANDA 30 sections
DAPTOMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 16729-435 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 30 sections
DAPTOMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 16729-435 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 30 sections
daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 25021-174 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 31 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 25021-179 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 33 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 25021-179 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 33 sections
Daptomycin Human Prescription Drug Label 1 31722-102 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 28 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 31722-215 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS ANDA 29 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 31722-215 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS ANDA 29 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 31722-216 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 27 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 42023-295 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 27 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 42023-295 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 27 sections
daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 42658-011 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 27 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 43598-413 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 26 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 43598-476 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS ANDA 27 sections
Daptomycin Human Prescription Drug Label 1 45932-0039 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 29 sections